Li Yang, Kanzaki Sho, Shibata Shinsuke, Nakamura Masaya, Ozaki Masahiro, Okano Hideyuki, Ogawa Kaoru
Department of Otolaryngology Head and Neck Surgery, Keio University School of Medicine, Tokyo, Japan.
Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China.
Front Neurol. 2021 Aug 19;12:641593. doi: 10.3389/fneur.2021.641593. eCollection 2021.
Although combination of oral and transtympanic drug therapy (CT) has been proved more effective and safer for idiopathic sudden sensorineural hearing loss (ISSNHL) by some clinical trials, there are few laboratory researches on the pharmacokinetics in the inner ear following CT on account of structural limitations of the inner ear. The aim of the present study was to investigate the pharmacokinetic behaviors of CT in the inner ear of mice. Eighteen transgenic mice which express luciferase in cochlear spiral ganglion cells were divided into oral administration (OR) group, transtympanic injection route (TT) group and CT group, and luciferin was delivered into the inner ear of these mice through oral, transtympanic or combined routes, respectively. A new imaging system was used to observe luciferin/luciferase signals and the compare the pharmacokinetics of different administration routes in the inner ear of mice. Bioluminescence signals were observed in the inner ear 3.3 ± 2.6 min after CT, significantly earlier than that of OR group (15.8 ± 7.4 min). CT owned the longest reaching-peak time and largest area under the curve (AUC) among three groups. Compared to TT, CT had longer biological half-life and higher AUC value, but did not displayed stronger peak value. There were significant differences in the peak values between OR group and TT group and between OR group and CT group. This study suggests that the OR route is less effective than the TT or CT route, and combination of OR and TT can deliver more drugs into the inner ear and confer a longer therapeutic window, but cannot increase drug intensity.
尽管一些临床试验已证明口服与经鼓膜联合药物治疗(CT)对特发性突发性感音神经性听力损失(ISSNHL)更有效且更安全,但由于内耳的结构限制,关于CT后内耳药代动力学的实验室研究很少。本研究的目的是研究CT在小鼠内耳中的药代动力学行为。将18只在耳蜗螺旋神经节细胞中表达荧光素酶的转基因小鼠分为口服给药(OR)组、经鼓膜注射途径(TT)组和CT组,分别通过口服、经鼓膜或联合途径将荧光素输送到这些小鼠的内耳中。使用一种新的成像系统观察荧光素/荧光素酶信号,并比较不同给药途径在小鼠内耳中的药代动力学。CT后3.3±2.6分钟在内耳中观察到生物发光信号,明显早于OR组(15.8±7.4分钟)。CT在三组中达到峰值的时间最长,曲线下面积(AUC)最大。与TT相比,CT的生物半衰期更长,AUC值更高,但峰值不强。OR组与TT组之间以及OR组与CT组之间的峰值存在显著差异